NLS Pharmaceutics (NLSP) Competitors $1.95 -0.43 (-18.07%) (As of 12/20/2024 05:40 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends NLSP vs. NXTC, FBRX, KALA, DARE, LGVN, LPCN, PLUR, LVTX, NAII, and ENLVShould you be buying NLS Pharmaceutics stock or one of its competitors? The main competitors of NLS Pharmaceutics include NextCure (NXTC), Forte Biosciences (FBRX), KALA BIO (KALA), Daré Bioscience (DARE), Longeveron (LGVN), Lipocine (LPCN), Pluri (PLUR), LAVA Therapeutics (LVTX), Natural Alternatives International (NAII), and Enlivex Therapeutics (ENLV). These companies are all part of the "pharmaceutical products" industry. NLS Pharmaceutics vs. NextCure Forte Biosciences KALA BIO Daré Bioscience Longeveron Lipocine Pluri LAVA Therapeutics Natural Alternatives International Enlivex Therapeutics NLS Pharmaceutics (NASDAQ:NLSP) and NextCure (NASDAQ:NXTC) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, community ranking, institutional ownership, media sentiment, risk, valuation, dividends, profitability and analyst recommendations. Do insiders and institutionals hold more shares of NLSP or NXTC? 42.7% of NextCure shares are held by institutional investors. 16.4% of NLS Pharmaceutics shares are held by company insiders. Comparatively, 13.3% of NextCure shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Does the MarketBeat Community believe in NLSP or NXTC? NextCure received 72 more outperform votes than NLS Pharmaceutics when rated by MarketBeat users. Likewise, 64.52% of users gave NextCure an outperform vote while only 57.14% of users gave NLS Pharmaceutics an outperform vote. CompanyUnderperformOutperformNLS PharmaceuticsOutperform Votes857.14% Underperform Votes642.86% NextCureOutperform Votes8064.52% Underperform Votes4435.48% Do analysts rate NLSP or NXTC? NextCure has a consensus price target of $4.00, suggesting a potential upside of 312.37%. Given NextCure's stronger consensus rating and higher probable upside, analysts clearly believe NextCure is more favorable than NLS Pharmaceutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NLS Pharmaceutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00NextCure 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has preferable valuation and earnings, NLSP or NXTC? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNLS PharmaceuticsN/AN/A-$12.17MN/AN/ANextCureN/AN/A-$62.72M-$2.09-0.46 Does the media refer more to NLSP or NXTC? In the previous week, NLS Pharmaceutics had 1 more articles in the media than NextCure. MarketBeat recorded 2 mentions for NLS Pharmaceutics and 1 mentions for NextCure. NLS Pharmaceutics' average media sentiment score of 0.21 beat NextCure's score of -0.55 indicating that NLS Pharmaceutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NLS Pharmaceutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral NextCure 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative Is NLSP or NXTC more profitable? NLS Pharmaceutics' return on equity of 0.00% beat NextCure's return on equity.Company Net Margins Return on Equity Return on Assets NLS PharmaceuticsN/A N/A N/A NextCure N/A -62.50%-53.67% Which has more risk & volatility, NLSP or NXTC? NLS Pharmaceutics has a beta of -0.52, suggesting that its stock price is 152% less volatile than the S&P 500. Comparatively, NextCure has a beta of 0.63, suggesting that its stock price is 37% less volatile than the S&P 500. SummaryNextCure beats NLS Pharmaceutics on 7 of the 13 factors compared between the two stocks. Ad Crypto 101 MediaThe #1 Coin for November 2024Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this newly established trust, I believe this coin could skyrocket up to 150x+ in the next 30 days alone! I've compiled everything you need to know about this once-in-a-lifetime DeFi project into a brand-new comprehensive guide… You can get access to the report by clicking here now… Get NLS Pharmaceutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NLSP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NLSP vs. The Competition Export to ExcelMetricNLS PharmaceuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.44M$6.57B$5.14B$9.08BDividend YieldN/A3.00%5.09%4.23%P/E RatioN/A10.5589.7417.16Price / SalesN/A196.061,117.09117.04Price / CashN/A57.1643.1037.86Price / Book0.185.094.784.78Net Income-$12.17M$151.83M$120.31M$225.60M7 Day Performance2.09%-2.14%-1.92%-1.23%1 Month Performance-43.15%-4.56%13.65%0.46%1 Year Performance347.15%8.87%28.34%15.24% NLS Pharmaceutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NLSPNLS Pharmaceutics0.364 of 5 stars$1.95-18.1%N/A+336.9%$7.44MN/A0.006News CoverageGap UpNXTCNextCure4.2217 of 5 stars$1.02-5.6%$4.00+292.2%-13.4%$28.57MN/A-0.5290Positive NewsFBRXForte Biosciences1.6802 of 5 stars$19.54-15.6%$23.58+20.7%+65,414.9%$28.53MN/A-1.315KALAKALA BIO3.8466 of 5 stars$6.11-1.1%$15.00+145.5%-14.8%$28.17M$3.89M-0.5030Gap DownDAREDaré Bioscience1.5891 of 5 stars$3.18flat$24.00+654.7%-28.4%$27.67M$1.88M-5.3930Analyst ForecastGap DownLGVNLongeveron3.4375 of 5 stars$1.84-1.3%$8.67+372.3%-86.8%$27.23M$1.89M-0.3023LPCNLipocine1.5291 of 5 stars$4.97-1.0%$10.00+101.2%+66.5%$26.58M$7.92M-6.6110News CoveragePLURPluri0.4276 of 5 stars$4.71-0.2%N/A+5.9%$26.19M$330,000.000.00150News CoveragePositive NewsLVTXLAVA Therapeutics3.0636 of 5 stars$1.03-7.2%$4.67+353.1%-31.8%$26.11M$7.35M-1.0860Analyst ForecastGap DownNAIINatural Alternatives InternationalN/A$4.21-2.1%N/A-35.9%$26.10M$112.98M-2.99290Analyst ForecastENLVEnlivex Therapeutics2.321 of 5 stars$1.17-2.5%$9.50+712.0%-45.6%$25.05MN/A0.0070 Related Companies and Tools Related Companies NextCure Alternatives Forte Biosciences Alternatives KALA BIO Alternatives Daré Bioscience Alternatives Longeveron Alternatives Lipocine Alternatives Pluri Alternatives LAVA Therapeutics Alternatives Natural Alternatives International Alternatives Enlivex Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NLSP) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredMUST SEE: The most important video in the world right now?If you have a significant amount of money in the stock market right now — or if you're sitting on the sideline...InvestorPlace | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NLS Pharmaceutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share NLS Pharmaceutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
